[1] Rutter A, Luger TA. High-dose intravenous immunoglobulins:an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol,2001, 44:1010-1024.
[2] Pyne D, Ehrenstein M, Morris V.The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases.Rheumatology (Oxford). 2002, 41:367-374.
[3] Gelfand EW. Use of IGIV in the treatment of immune-mediated dermatologic disorders.J Investig Dermatol Symp Proc, 2004, 9:92-96.
[4] Akashi K, Nagasawa K, Mayumi T, et al.Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J Rheumatol, 1990, 17:375-379.
[5] Maier WP, Gordon DS, Howard RF, et al.Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum, 1990,33:1233-1239.
[6] Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis:an open study in 11 adult patients. J Rheumatol, 1994, 21:1092-1097.
[7] Dalakas MC. High-dose intravenous immunoglobulin in inflammatory myopathies:experience based on controlled clinical trials. Neurol Sci, 2003, 24:S256-259.
[8] Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol, 1996, 35:1150-1153.
[9] Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM, 2000, 93:433-439.
[10] Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol, 2003, 139:1051-1059.
[11] Goebeler M, Seitz C, Rose C, et al. Successful treatment of linear IgA disease with salazosulphapyridine and intravenous immunoglobulins. Br J Dermatol, 2003, 149:912-914.
[12] Sidwell RU, Swift S, Yan CL, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin. Int J Clin Pract,2003, 57:643-645.
[13] Trent JT, Kerdel FA. Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis. Arch Dermatol, 2003,139:1081.
[14] Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis:seven cases and review of the literature. Pediatrics, 2003, 112:1430-1436.
[15] Rutter A, Luger TA. Intravenous immunoglobulin:an emerging treatment for immune-mediated skin diseases. Curr Opin Investig Drugs, 2002, 3:713-719.
[16] 陈树明,张法义.静脉滴注免疫球蛋白治疗自身免疫性皮病.国外医学皮肤性病学分册,1997,6:323-325. |
